AstraZeneca's IL-33-targeting antibody tozorakimab has hit the target in the third of three phase 3 trials in chronic obstructive pulmonary disease (COPD), making a clean sweep of results and setting ...

Third positive pivotal Phase III clinical trial of AstraZeneca’s IL-33-targeting biologic further demonstrates its benefits in COPD Positive high-level results from the pivotal Phase III MIRANDA trial ...

First-ever IL-33-targeting biologic to demonstrate statistically significant and highly clinically meaningful reductions in COPD exacerbations in two replicate Phase III clinical trials WILMINGTON, ...

April 20 (Reuters) - AstraZeneca (AZN.L), opens new tab said on Monday its ‌experimental treatment tozorakimab showed a "meaningful reduction" in moderate-to-severe flare-ups of chronic obstructive ...

Jefferies believes detailed data on AstraZeneca PLC's (LSE:AZN, NASDAQ:AZN) experimental lung drug tozorakimab could more than compensate investors for the recent failure of a separate heart trial.

AstraZeneca (AZN) announced an update on their ongoing clinical study. AstraZeneca recently completed a clinical study titled ‘A Multiple Centre, Randomised, Open-label, Parallel Group, Phase I ...

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. AstraZeneca (LSE:AZN) reported that its monoclonal ...

Britain's most valuable company said its experimental lung disease medicine met its target in two late-stage clinical trials. The respiratory treatment Tozorakimab, reduced flare-ups of chronic ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the Phase III OBERON and TITANIA trials in patients with chronic obstructive pulmonary disease (COPD) showed that tozorakimab ...